View Future GrowthPerk Labs 過去の業績過去 基準チェック /06Perk Labsの過去数年間の業績に関するデータが不十分です。主要情報n/a収益成長率n/aEPS成長率Software 業界の成長17.33%収益成長率n/a株主資本利益率n/aネット・マージンn/a前回の決算情報31 Aug 2023最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Jun 14Perk Labs Inc. announced that it expects to receive CAD 2.5 million in fundingPerk Labs Inc. announced a non-brokered private placements of units and convertible debentures on June 12, 2024. The Company is proposing a new non-brokered private placement of up to 115,384,615 units at a price of CAD 0.013 per Unit for gross proceeds of up to CAD 1,499,999.995 and convertible debentures for gross proceeds of up to CAD 1,000,000; aggregate gross proceeds of CAD 2,499,999.995. Each Unit will consist of one common share and one Common Share purchase warrant. Each Warrant will entitle the holder to purchase one additional Common Share at a price of CAD 0.05 per Common Share for a period of 24 months from the Closing. The convertible debentures will be offered for a 2-year term at an interest rate of 15% and will be convertible into common shares of Perk Labs at a conversion price of CAD 0.05 per share. The private placements of the Units and the convertible debentures are expected to close on or before June 29, 2024. The Closing is subject to customary closing conditions, including, but not limited to, the receipt of all necessary approvals. All securities issued pursuant to the private placements will be subject to a statutory hold period of four months and one day following the Closing. A finder’s fee may be payable in connection with the Private Placements.お知らせ • Apr 26Perk Labs Inc. announced that it has received CAD 1.714 million in fundingOn April 25, 2024, Perk Labs Inc. closed the transaction. The company announced that it has issued 78,900,000 units at a price of CAD 0.01 per unit for the gross proceeds of CAD 789,000 and 15% convertible debentures for the gross proceeds of CAD 25,000; aggregate gross proceeds of CAD 814,000 in third and final tranche. Each Unit consists of one common share and one Common Share purchase warrant. Each Warrant will entitle the holder to purchase one additional Common Share at a price of CAD 0.05 per Common Share for a period of 24 months from the closing. The Debentures mature two years from the date of issuance and bear interest at a rate of 15% per annum. The Debentures are convertible into Common Shares at a conversion price of CAD 0.05 per Common Share, subject to the terms and conditions set forth in the specific Debenture agreement. All securities issued pursuant to the private placements are subject to a statutory hold period of four months and one day following the closing. In connection with private placements, B. Rogic acquired CAD 73,000 of Unitsお知らせ • Dec 14+ 1 more updatePerk Labs Inc. Announces Issuance of U.S. PatentPerk Labs Inc. announced the issuance of its United States patent that protects the Company's rights to one of its inventions for systems and methods for electronic payments with fraud prevention, based on correlating transaction data and information from a user's device.お知らせ • Sep 29Perk Labs Inc. announced that it has received CAD 0.471 million in fundingOn September 28, 2023, Perk Labs Inc. closed the transaction. The company issued 1,312,500 units at an issue price of CAD 0.016 per unit for the gross proceeds of CAD 21,000 and convertible debentures for the gross proceeds of CAD 450,000; aggregate gross proceeds of CAD 471,000. Each Unit consists of one common share and one Common Share purchase warrant. Each Warrant will entitle the holder to purchase one additional Common Share at a price of CAD 0.05 per Common Share for a period of 24 months from the closing. The Debentures mature one year from the date of issuance and bear interest at a rate of 15% per annum. The Debentures are convertible into Common Shares at a conversion price of CAD 0.05 per Common Share. All securities issued pursuant to the private placements are subject to a statutory hold period of four months and one day following the closing. The bonds will mature on September 28, 2024.お知らせ • Jul 15+ 1 more updatePerk Labs Inc. announced that it expects to receive CAD 0.35 million in fundingPerk Labs Inc. announced a non-brokered private placement of 6,250,000 units at an issue price of CAD 0.016 per unit for the gross proceeds of up to CAD 100,000 and convertible debentures for the gross proceeds of CAD 250,000, for the aggregate gross proceeds of CAD 350,000 on July 14, 2023. Each Unit will consist of one common share and one Common Share purchase warrant. Each Warrant will entitle the holder to purchase one additional Common Share at a price of CAD 0.05 per common share for a period of 24 months from the Closing. The convertible debentures will be offered on varying terms, including interest rates ranging from 5% to 15% and differing acceleration terms and maturity dates specific to the terms of each convertible debenture agreement. The convertible debentures will be convertible into common shares of Perk Labs at a conversion price of CAD 0.05 per share, subject to the terms and conditions set forth in the specific convertible debenture agreement. The Closing is subject to customary closing conditions, including, but not limited to, the receipt of all necessary approvals. All securities issued pursuant to the private placement will be subject to a statutory hold period of four months and one day following the Closing. The private placement of the Units and the convertible debentures is expected to close on or before August 24, 2023.お知らせ • Jul 10Perk Labs Inc. Announces Patrick Power Resigns from BoardPerk Labs Inc. at its Annual General Meeting of Shareholders held on July 5, 2023, announced Patrick Power has submitted his resignation to the Board. After review and consideration, the Board has accepted Mr. Power's resignation.お知らせ • May 25Perk Labs Inc., Annual General Meeting, Jul 05, 2023Perk Labs Inc., Annual General Meeting, Jul 05, 2023.お知らせ • Jan 21Perk Labs Inc. Announces CFO TransitionPerk Labs Inc. announced that effective February 17, 2023, Andrew Bailes, a seasoned finance executive, will succeed Ms. Altamirano as Interim CFO until a permanent CFO is named. Vanessa Altamirano will step down effective February 17, 2023 to pursue another professional opportunity. Perk is currently in the process of structuring a merger with Getit Technologies Inc. (‘Getit’), and as part of the process, the Company continues to review its team to optimise the integration of the two companies. Andrew Bailes is a Chartered Public Accountant, Principal at Hertford Advisors and has served in CFO roles since 2006. He has extensive experience in IT, Telecoms, Logistics, manufacturing and other sectors, managing finance and Legal, HR and Operational functions. Andrew did his undergraduate degree in Mathematics and Management Studies at Cambridge University in the UK and was top in his Executive MBA at Cornell and Queens. His notable achievements include: CFO for various capital raises totaling over $100 million Negotiation of many multi-million dollar debt facilities Head of a 25-man Finance Department at one of Ottawa's larger production facilities Twenty-five years' experience in Business and Strategic planning .お知らせ • Jan 05Perk Labs Inc. Appoints Patrick Power to the Board of DirectorsPerk Labs Inc. announced that it has appointed Mr. Patrick Power to the company's board of directors, effective immediately. Mr. Power brings a wealth of experience in business and finance to the board. He is the Chairman and President of James Edward Capital Corporation, an Ottawa-based boutique investment bank focused on emerging growth companies and is advising the Company on its strategic options. Mr. Power has significant experience in finance and governance, having previously served in senior executive roles for several TSX/TSXV-listed technology companies.収支内訳Perk Labs の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:PKLB.F 収益、費用、利益 ( )CAD Millions日付収益収益G+A経費研究開発費31 Aug 230-21131 May 230-21128 Feb 230-31130 Nov 220-32131 Aug 220-32131 May 220-42128 Feb 220-42130 Nov 210-12131 Aug 210-23131 May 210-23128 Feb 210-23130 Nov 200-42131 Aug 200-50331 May 200-80329 Feb 200-143330 Nov 190-84331 Aug 190-610-231 May 191-611-128 Feb 191-311030 Nov 182-1314031 Aug 182-1816231 May 182-1716128 Feb 182-1413130 Nov 171-109131 Aug 170-54131 May 170-43028 Feb 170-32030 Nov 160-22031 Aug 160-11031 May 160-11029 Feb 160-100質の高い収益: PKLB.Fが 高品質の収益 を有しているかどうかを判断するにはデータが不十分です。利益率の向上: PKLB.Fの 利益率 が過去 1 年間で改善したかどうかを判断するにはデータが不十分です。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: PKLB.Fの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: PKLB.Fの過去 1 年間の収益成長を 5 年間の平均と比較するにはデータが不十分です。収益対業界: PKLB.Fの過去 1 年間の収益成長がSoftware業界平均を上回ったかどうかを判断するにはデータが不十分です。株主資本利益率高いROE: PKLB.Fは現在利益が出ていないため、自己資本利益率 ( 0% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YSoftware 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/19 08:10終値2026/05/12 00:00収益2023/08/31年間収益2022/11/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Perk Labs Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jun 14Perk Labs Inc. announced that it expects to receive CAD 2.5 million in fundingPerk Labs Inc. announced a non-brokered private placements of units and convertible debentures on June 12, 2024. The Company is proposing a new non-brokered private placement of up to 115,384,615 units at a price of CAD 0.013 per Unit for gross proceeds of up to CAD 1,499,999.995 and convertible debentures for gross proceeds of up to CAD 1,000,000; aggregate gross proceeds of CAD 2,499,999.995. Each Unit will consist of one common share and one Common Share purchase warrant. Each Warrant will entitle the holder to purchase one additional Common Share at a price of CAD 0.05 per Common Share for a period of 24 months from the Closing. The convertible debentures will be offered for a 2-year term at an interest rate of 15% and will be convertible into common shares of Perk Labs at a conversion price of CAD 0.05 per share. The private placements of the Units and the convertible debentures are expected to close on or before June 29, 2024. The Closing is subject to customary closing conditions, including, but not limited to, the receipt of all necessary approvals. All securities issued pursuant to the private placements will be subject to a statutory hold period of four months and one day following the Closing. A finder’s fee may be payable in connection with the Private Placements.
お知らせ • Apr 26Perk Labs Inc. announced that it has received CAD 1.714 million in fundingOn April 25, 2024, Perk Labs Inc. closed the transaction. The company announced that it has issued 78,900,000 units at a price of CAD 0.01 per unit for the gross proceeds of CAD 789,000 and 15% convertible debentures for the gross proceeds of CAD 25,000; aggregate gross proceeds of CAD 814,000 in third and final tranche. Each Unit consists of one common share and one Common Share purchase warrant. Each Warrant will entitle the holder to purchase one additional Common Share at a price of CAD 0.05 per Common Share for a period of 24 months from the closing. The Debentures mature two years from the date of issuance and bear interest at a rate of 15% per annum. The Debentures are convertible into Common Shares at a conversion price of CAD 0.05 per Common Share, subject to the terms and conditions set forth in the specific Debenture agreement. All securities issued pursuant to the private placements are subject to a statutory hold period of four months and one day following the closing. In connection with private placements, B. Rogic acquired CAD 73,000 of Units
お知らせ • Dec 14+ 1 more updatePerk Labs Inc. Announces Issuance of U.S. PatentPerk Labs Inc. announced the issuance of its United States patent that protects the Company's rights to one of its inventions for systems and methods for electronic payments with fraud prevention, based on correlating transaction data and information from a user's device.
お知らせ • Sep 29Perk Labs Inc. announced that it has received CAD 0.471 million in fundingOn September 28, 2023, Perk Labs Inc. closed the transaction. The company issued 1,312,500 units at an issue price of CAD 0.016 per unit for the gross proceeds of CAD 21,000 and convertible debentures for the gross proceeds of CAD 450,000; aggregate gross proceeds of CAD 471,000. Each Unit consists of one common share and one Common Share purchase warrant. Each Warrant will entitle the holder to purchase one additional Common Share at a price of CAD 0.05 per Common Share for a period of 24 months from the closing. The Debentures mature one year from the date of issuance and bear interest at a rate of 15% per annum. The Debentures are convertible into Common Shares at a conversion price of CAD 0.05 per Common Share. All securities issued pursuant to the private placements are subject to a statutory hold period of four months and one day following the closing. The bonds will mature on September 28, 2024.
お知らせ • Jul 15+ 1 more updatePerk Labs Inc. announced that it expects to receive CAD 0.35 million in fundingPerk Labs Inc. announced a non-brokered private placement of 6,250,000 units at an issue price of CAD 0.016 per unit for the gross proceeds of up to CAD 100,000 and convertible debentures for the gross proceeds of CAD 250,000, for the aggregate gross proceeds of CAD 350,000 on July 14, 2023. Each Unit will consist of one common share and one Common Share purchase warrant. Each Warrant will entitle the holder to purchase one additional Common Share at a price of CAD 0.05 per common share for a period of 24 months from the Closing. The convertible debentures will be offered on varying terms, including interest rates ranging from 5% to 15% and differing acceleration terms and maturity dates specific to the terms of each convertible debenture agreement. The convertible debentures will be convertible into common shares of Perk Labs at a conversion price of CAD 0.05 per share, subject to the terms and conditions set forth in the specific convertible debenture agreement. The Closing is subject to customary closing conditions, including, but not limited to, the receipt of all necessary approvals. All securities issued pursuant to the private placement will be subject to a statutory hold period of four months and one day following the Closing. The private placement of the Units and the convertible debentures is expected to close on or before August 24, 2023.
お知らせ • Jul 10Perk Labs Inc. Announces Patrick Power Resigns from BoardPerk Labs Inc. at its Annual General Meeting of Shareholders held on July 5, 2023, announced Patrick Power has submitted his resignation to the Board. After review and consideration, the Board has accepted Mr. Power's resignation.
お知らせ • May 25Perk Labs Inc., Annual General Meeting, Jul 05, 2023Perk Labs Inc., Annual General Meeting, Jul 05, 2023.
お知らせ • Jan 21Perk Labs Inc. Announces CFO TransitionPerk Labs Inc. announced that effective February 17, 2023, Andrew Bailes, a seasoned finance executive, will succeed Ms. Altamirano as Interim CFO until a permanent CFO is named. Vanessa Altamirano will step down effective February 17, 2023 to pursue another professional opportunity. Perk is currently in the process of structuring a merger with Getit Technologies Inc. (‘Getit’), and as part of the process, the Company continues to review its team to optimise the integration of the two companies. Andrew Bailes is a Chartered Public Accountant, Principal at Hertford Advisors and has served in CFO roles since 2006. He has extensive experience in IT, Telecoms, Logistics, manufacturing and other sectors, managing finance and Legal, HR and Operational functions. Andrew did his undergraduate degree in Mathematics and Management Studies at Cambridge University in the UK and was top in his Executive MBA at Cornell and Queens. His notable achievements include: CFO for various capital raises totaling over $100 million Negotiation of many multi-million dollar debt facilities Head of a 25-man Finance Department at one of Ottawa's larger production facilities Twenty-five years' experience in Business and Strategic planning .
お知らせ • Jan 05Perk Labs Inc. Appoints Patrick Power to the Board of DirectorsPerk Labs Inc. announced that it has appointed Mr. Patrick Power to the company's board of directors, effective immediately. Mr. Power brings a wealth of experience in business and finance to the board. He is the Chairman and President of James Edward Capital Corporation, an Ottawa-based boutique investment bank focused on emerging growth companies and is advising the Company on its strategic options. Mr. Power has significant experience in finance and governance, having previously served in senior executive roles for several TSX/TSXV-listed technology companies.